VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action

VYNE Therapeutics Inc VYNE announced preclinical data for VYN201, its pan-bromodomain and extra-terminal (BET) inhibitor.
The data showed that VYN201 significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune diseases in an animal model and an ex vivo human tissue study.
The pathogenesis of many autoimmune diseases is linked to the proliferation and activity of Th17 cells.
Treatment with VYN201 0.1% resulted in a 94% reduction in the composite inflammation severity score of erythema and scaling relative to the vehicle control group at treatment day 7
Animals treated with VYN201 0.1% experienced reduced inflammation comparable to those treated with the class 1 super-potent glucocorticosteroid clobetasol propionate 0.05% cream.
Treatment with VYN201 at all concentrations appeared well-tolerated
Related: VYNE Therapeutics Stock Drops On the Potential Sale Of Topical Minocycline Franchise.
Price Action: VYNE shares are up 11.90% at $1.32 during the market session on the last check Tuesday.